News

OCRF Research Pinpoints Two Genes that Trigger Ovarian Cancer

(January 28, 2015) OCRF grantee Ron Chandler, PhD developed a mouse model of clear cell ovarian cancer and found a potential route to better treatments and much-needed diagnostic screens. Dr. Chandler spearheaded a team of researchers at University of North Carolina that developed a mouse model of clear... 

Veliparib Trial Fails to Improve Outcomes in Ovarian Cancer

(January 26, 2015) Use of the PARP inhibitor veliparib in combination with oral cyclophosphamide did not result in an improvement in response rate or median progression-free survival compared with treatment with cyclophosphamide alone, according to a phase II study evaluating patients with high-grade... 

BRCA1/2 Mutations and 10 year Survival in Ovarian Cancer

(January 22, 2015) In a study published in Clinical Cancer Research, researchers analyzed the effect of germline mutations in BRCA1 and BRCA2 on mortality in ovarian cancer patients up to ten years after diagnosis. The researchers found that BRCA1/2 mutations are associated with better short-term survival,... 

Ovarian Cancer Will Continue to be Sequenced After The Cancer Genome Atlas Ends

The Cancer Genome Atlas (TCGA), a massive U.S. effort to genetically profile 10,000 tumors, has officially come to an end. The National Cancer Institute (NCI) has announced that it will continue to intensively sequence tumors in three cancers, ovarian, colorectal and lung adenocarcinoma, with an expanded... 

Palliative Care Consultation Improves Symptoms in Gynecologic Cancer Patients

A new study published in Gynecologic Oncology found that palliative care consultation is associated with improvement in symptom burden, the majority of which occurs within one day of consultation. Palliative care (or treatment) relieves symptoms such as pain, and reduces the suffering caused by cancer.... 

FDA Approves Olaparib for Ovarian Cancer

(December 19, 2014) The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Olaparib (Lynparza) for advanced, BRCA-mutated ovarian cancer, the first approval of a drug in the PARP (poly ADP-ribose polymerase) inhibitor class. The FDA also approved Myriad Genetics’ BRACAnalysis... 

OCRF Research Shows Targeting microRNA May Benefit Some Ovarian Cancer Patients

(December 10, 2014) OCRF Ann Schreiber Mentored Investigator Award Grantee, Pradeep Chaluvally-Raghavan, Ph.D., and other researchers at The University of Texas MD Anderson Cancer Center believe they may have found a molecule-based approach to halting the destructive nature of a genetic misfire called... 

Population Screening for BRCA Mutations in Ashkenazi Jewish Women is Cost-Effective

Population-based testing for BRCA 1/2 gene mutations detects the high proportion of carriers not identified by cancer family history (FH)-based testing. A new study published in the Journal of the National Cancer Institute compared the cost-effectiveness of population-based BRCA testing with the standard... 

Thank You for 20 Years of Hope Through Research

“In 1989, my wife Ann was diagnosed with ovarian cancer. At that time, there wasn’t much information on the disease, and there was little research being funded. While Ann bravely battled the disease, I spoke with the families and friends of other ovarian cancer patients. Together, we learned... 

Ovarian Cancer Research Fund Legends Gala

OCRF’s 20th Anniversary Legends Gala, hosted by Harry Connick, Jr., was held on Wednesday,  November 5th at The Pierre Hotel in New York City. Honorees included the Janet Burros Memorial Foundation, Chris Salgardo, President of Kiehl’s Since 1851, and Pierce Brosnan. The event also included...